Mahidol University

Green Development of Mahidol University in Thailand

Retrieved on: 
Friday, September 8, 2023
AFCI, Firefighter, Engineering Institute, Tree, Smart, DC, Electricity, Research, Carbon, PV, ESS, EIT, Student, US, Mahidol University, Laboratory, COP26, O&M, Faculty, L4, C&I, Safety, Renewable energy, Huawei

SHENZHEN, China, Sept. 8, 2023 /PRNewswire/ -- Mahidol University is a century-old, renowned university located in southern Thailand.

Key Points: 
  • SHENZHEN, China, Sept. 8, 2023 /PRNewswire/ -- Mahidol University is a century-old, renowned university located in southern Thailand.
  • Mahidol University is not only a leading educator, but also a pioneer in exploring carbon neutrality in Thailand.
  • The Smart PV+ESS system of Mahidol University not only provides green energy for the campus, but also reduces carbon emissions and electricity costs.
  • In addition, it provides students with a platform for close access to and research on green power operation, and sets a benchmark for Thailand to develop distributed PV.

Quantum Leap in Blockchain Gaming, Nakamoto Games Expanding Footprint across Thai Universities

Retrieved on: 
Wednesday, June 28, 2023
University, Blockchain, Partnership, Student, Mahidol University, Economics, Machine learning, Cryptocurrency, Video game

Staying true to its commitment to nurture fresh talent and propel innovation in blockchain technology, Nakamoto Games has integrated its platform into the curricula of premier Thai institutions.

Key Points: 
  • Staying true to its commitment to nurture fresh talent and propel innovation in blockchain technology, Nakamoto Games has integrated its platform into the curricula of premier Thai institutions.
  • The company has successfully joined forces with numerous Thai government bodies, advocating for synchronized crypto policies with blockchain incentive structures.
  • The inclusion of Nakamoto Games in the economics syllabi of Thailand's top universities is a testament to the gaming platform's success.
  • With approximately 20 million students in Thailand, Nakamoto Games is projected to attract at least 2 million new users to its platform.

ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand

Retrieved on: 
Thursday, April 6, 2023
Medical school, Uranium hexafluoride, SIV, Safety, Retinal detachment, Clinical trial, SF6, CNS, Khon Kaen University, Ramathibodi Hospital, Srinagarind Hospital, Mahidol University, Patient, Ophthalmology, Effectiveness, Phase, Visual acuity, Pharmaceutical industry, Nursing, Medicine

Fremont, CA, April 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Vitargus® Phase II Site Initiation Visit (SIV) at Ramathibodi Hospital, Faculty of Medicine, Mahidol University (TH001) in Thailand was successfully conducted on March 22, 2023.

Key Points: 
  • Fremont, CA, April 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Vitargus® Phase II Site Initiation Visit (SIV) at Ramathibodi Hospital, Faculty of Medicine, Mahidol University (TH001) in Thailand was successfully conducted on March 22, 2023.
  • The SIV was an organized meeting to discuss the Phase II study protocol with the principal investigator, Duangnate Rojanaporn, M.D.
  • The Phase II study screening and enrollment has been initiated and will aim to enroll at least 40 patients across all four sites in Australia and Thailand.
  • “We are currently enrolling patients at Srinagarind Hospital, Khon Kaen University (TH002), which completed its SIV on March 10, 2023.

A Total of Approximately 400 Million Yen Investment in Eisai, Ehime University, DNDi and Others for New Drug and Vaccine Development for Neglected Tropical Diseases

Retrieved on: 
Thursday, March 30, 2023
Mycetoma, Vaccine, Partnership, Neglected tropical diseases, Government of Japan, United Nations, Amputation, Onchocerciasis, Eumycetoma, Global Health Innovative Technology Fund, UNDP, Global health, Research, Infection, Attention, Ehime University, Paratriathlon, Fungus, Messenger, University Hospital Bonn, Eisai, PPP, US, Tropical disease, Mahidol University, NTD, Tuberculosis, Patient, Investment, Wellcome, Parasitic disease, Parasitism, United Nations Development Programme, Onchocerca, Bill, Bacteria, WHO, Health, Bill & Melinda Gates Foundation, Pain, Virus, Onchocerca volvulus, Drugs for Neglected Diseases Initiative, World Health Organization, Disease, Malaria, Pharmaceutical industry

The GHIT Fund will invest approximately 300 million yen (US$2.2 million1) in a project by Eisai Co., Ltd. (Eisai) and Drugs for Neglected Diseases initiative (DNDi) for regulatory approval and to prepare for patient access to drugs for eumycetoma.

Key Points: 
  • The GHIT Fund will invest approximately 300 million yen (US$2.2 million1) in a project by Eisai Co., Ltd. (Eisai) and Drugs for Neglected Diseases initiative (DNDi) for regulatory approval and to prepare for patient access to drugs for eumycetoma.
  • Mycetoma, an NTD, is a progressive disease that destroys subcutaneous and deep tissues infected by bacterial or fungal invasion through a wound.
  • We hope this treatment will be quickly approved and reach patients as soon as possible, during GHIT's third five-year plan."
  • The GHIT Fund invests and manages an R&D portfolio of development partnerships aimed at neglected diseases, such as malaria, tuberculosis and neglected tropical diseases that afflict the world's vulnerable and underserved populations.

Mahidol University, the Top University in Thailand, Has Officially Adopted Jolly Good's Medical VR

Retrieved on: 
Wednesday, November 30, 2022
COVID-19, Chakri Naruebodindra Medical Institute, Infection, Tropical medicine, Public health, Jane and Robert Cizik School of Nursing, Environment, Juntendo University, Institute for Health Metrics and Evaluation, Seven Is a Jolly Good Time, MHLW, Feel Good Inc., Zaporizhzhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine, Hospital, Ministry, Knowledge, Physician, Ramathibodi Hospital, Education, Faculty, Death, Evaluation, Faculty of Tropical Medicine, Mahidol University, Mahidol University, School, Chūō-ku, Ministry of Health, Labour and Welfare, ICT, VR, Public, Medicine, Pharmaceutical industry, Tutoring, Health, Nursing

TOKYO, Nov. 30, 2022 /PRNewswire/ -- Jolly Good Inc. (Chuo-ku, Tokyo, CEO: Kensuke Joji, hereinafter referred to as "Jolly Good"), in collaboration with Juntendo University (Bunkyo-ku, Tokyo, President: Hajime Arai), will commence a demonstration project for the introduction of medical education VR for the purpose of developing medical human resources through the use of VR at Royal Mahidol University (Bangkok, Thailand, President: Prof. Banchong Mahaisavariya, hereinafter referred to as "Mahidol University") and throughout Thailand. This is the first time that Japanese medical VR has been officially introduced into an overseas university.

Key Points: 
  • This is the first time that Japanese medical VR has been officially introduced into an overseas university.
  • In this project, Jolly Good will provide Mahidol University with VR teaching material production facilities and VR experience equipment to create an environment that enables the self-production of VR teaching materials for infectious disease treatment education at the university.
  • Year 1: Build a self-production environment for VR teaching materials at Mahidol University, complete the education program, and commence operation at the university.
  • In this seminar, professors from Mahidol University will give a remote VR lecture to medical students of Juntendo University in Japan by utilizing the educational VR of Infectious Disease Education produced at Mahidol University.

ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval

Retrieved on: 
Thursday, November 17, 2022
San Francisco, University, Khon Kaen University, Cedars-Sinai Medical Center, Ramathibodi Hospital, Patient, University of California, San Francisco, SIV, Ophthalmology, CNS, Security (finance), TGA, Mahidol University, Srinagarind Hospital, Risk, Trial of the century, FDA, Stanford University, Pharmaceutical industry, Import

FREMONT, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Vitargus Phase II Clinical Study Protocol has been approved by the Thailand Food and Drug Administration (FDA).

Key Points: 
  • FREMONT, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Vitargus Phase II Clinical Study Protocol has been approved by the Thailand Food and Drug Administration (FDA).
  • We are pleased that our two Vitargus Phase II study sites in Thailand have received Import licenses from the Thai FDA and can begin the study before the end of this year, said Dr. Howard Doong, Chief Executive Officer of the Company.
  • ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development.
  • For Vitargus, the company intends to conduct the clinical trials through Phase III at various locations throughout the globe.

Thousands of educators, policymakers & technology leaders assemble to discuss the future of education in Thailand

Retrieved on: 
Thursday, August 25, 2022
University, Lanko International Conference & Exhibition Tower D, Technology, Zoom, Khon Kaen University, Mahidol University, ICT, Thammasat University, Exhibition, Solution, Information technology, Tavaana: E-Learning Institute for Iranian Civil Society, Chiang Mai University, Amazon Web Services, KIS International School, Education, Graduate school, Faculty, Academy, Neuroscience, Faculty of Medicine Siriraj Hospital, Mahidol University, Learning, King Mongkut's University of Technology Thonburi, Publication, Conference, K–12, Google, Cognitive neuroscience, Heller School for Social Policy and Management, Policy, Institute, LIVE, Darunsikkhalai School for Innovative Learning, Dusit Thani College, Management, Tutoring, Lenovo, Coursera

Headlining the festival agenda is Chayaporn Wattanasiri, President of Mae Fah Lung University.

Key Points: 
  • Headlining the festival agenda is Chayaporn Wattanasiri, President of Mae Fah Lung University.
  • She'll be sharing higher education's move into the digital age, especially in the area of assessments.
  • Prof Jirapon Sunkpho, Vice President of Information Technology, Graduate Program in IT Policy and Management, Thammasat University
    - Asst.
  • The two-day free-to-attend conference and exhibition is expected to gather over 1,000 education stakeholders from Thailand and beyond.

ABVC BioPharma Provides Vitargus® Update

Retrieved on: 
Thursday, August 18, 2022
FDA, Safety, U.S. Securities and Exchange Commission, Risk, Srinagarind Hospital, Effectiveness, Forward-looking statement, CNS, Trial of the century, GLOBE, Technology, CA, EC, University of California, San Francisco, SEC, Stanford University, Hospital, Cedars-Sinai Medical Center, Ethics committee, Security (finance), Mahidol University, Ramathibodi Hospital, Company, TGA, NASDAQ, San Francisco, Faculty of Medicine Ramathibodi Hospital, Mahidol University, CTN, Ophthalmology, University, Pharmaceutical industry

FREMONT, CA, Aug. 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that, on August 2, 2022, approval was received from the Ethics Committee (EC) of the Ramathibodi Hospital, Mahidol University to conduct the Vitargus Phase II Study Protocol (ABV-1701-02). This follows a similar approval received on July 18, 2022, by Srinagarind Hospital, Khon Kaen University of Thailand.

Key Points: 
  • In parallel, Vitargus Phase II Study protocol documents have been submitted to the Australian Bellberry Human Research Ethics Committee (HREC).
  • ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development.
  • For Vitargus, the company intends to conduct the clinical trials through Phase III at various locations throughout the globe.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

ABVC BioPharma Provides Vitargus® Update

Retrieved on: 
Tuesday, August 2, 2022
Goal, CA, Stanford University, University, Cedars-Sinai Medical Center, GLOBE, TGA, U.S. Securities and Exchange Commission, Food, Ethics committee, EC, Forward-looking statement, SEC, Srinagarind Hospital, University of California, San Francisco, CNS, San Francisco, Ophthalmology, NASDAQ, Clinical trial, Review, Technology, Company, Security (finance), Patient, Ramathibodi Hospital, Phase, Risk, Mahidol University, Pharmaceutical industry

FREMONT, CA, Aug. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Ethics Committee (“EC”) of Srinagarind Hospital, Khon Kaen University of Thailand approved the Vitargus Phase II Clinical Study Protocol (ABV-1701-02). Srinagarind is one of two sites in Thailand that have agreed to participate in the study. The other site, Ramathibodi Hospital, Mahidol University, expects to receive EC approval in the near future. It is anticipated that a total of 20 or more patients undergoing vitreo-retinal surgery will be included in the studies at the selected sites. The final step prior to initiating the two studies is the issuance of an EC investigational product (IP) import license by the Food and Drug Administration of Thailand.

Key Points: 
  • FREMONT, CA, Aug. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Ethics Committee (EC) of Srinagarind Hospital, Khon Kaen University of Thailand approved the Vitargus Phase II Clinical Study Protocol (ABV-1701-02).
  • In addition, Vitargus Phase II Clinical Study protocol documents are now under review by the Australian Bellberry Human Research Ethics Committee (HREC).
  • ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

ABVC BioPharma Provides Vitargus® Update

Retrieved on: 
Thursday, June 30, 2022
Cedars-Sinai Medical Center, FDA, Patient, Srinagarind Hospital, Ramathibodi Hospital, Case report form, Glut: Mastering Information Through the Ages, University of California, San Francisco, EC, Khon Kaen University, GLOBE, Ophthalmology, CNS, Company, San Francisco, Mahidol University, U.S. Securities and Exchange Commission, Forward-looking statement, Ethics committee, National Research Council, Trial of the century, CRF, Technology, University, CA, CREC, SEC, Risk, NASDAQ, Stanford University, Security (finance), Pharmaceutical industry

FREMONT, CA, June 30, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Vitargus® Phase II Clinical Study Protocol has been approved by the Central Research Ethics Committee (CREC) of The National Research Council of Thailand. The approval encompasses the study protocol as well as the Master Informed Consent Form (Master ICF), Case Report Form (CRF) and the Investigator’s Brochure (IB), along with other relevant documents.

Key Points: 
  • FREMONT, CA, June 30, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Vitargus Phase II Clinical Study Protocol has been approved by the Central Research Ethics Committee (CREC) of The National Research Council of Thailand.
  • ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development.
  • For Vitargus, the company intends to conduct the clinical trials through Phase III at various locations throughout the globe.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.